Biohaven Ltd.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
Virgin Islands, British
Business Address
215 CHURCH STREET, NEW HAVEN, CT, 06510
Mailing Address
215 CHURCH STREET, NEW HAVEN, CT, 06510
Phone
203-404-0410
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
-$408.17M
Net Income
$399.38M
Total Liabilities
$538.77M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 19, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | March 13, 2026 | View on SEC |
| 4/A Insider transaction amendment | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 10-K Annual financial report | March 2, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
Annual Reports
10-K
March 2, 2026
- Strong cash position of $450 million providing a financial runway into late 2026.
- Diverse clinical-stage pipeline with lead candidates like Troriluzole (Phase 3) and Taldefgrobep Alfa (Phase 2/3) advancing.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.